Brief Review of Safety and Immunogenicity of Two RNA COVID19 Vaccines— Walsh 2020

This is a brief audio review. In the article Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates published, 2020 by Walsh and Colleagues, The outcomes and key points are as noted: BNT162b2 is a lipid nanoparticle formulated nucleoside modified ribonucleic acid based (referred to as a nanoparticle RNA vaccine) with a lower incidence and severity of adverse events than BNT162b1, which was another nanoparticle RNA vaccine. In both younger and older adults, the two vaccines produced comparable dose-dependent SARS-CoV-2–neutralizing antibody response geometric mean titers. The authors state that geometric mean titer results were comparable or greater than that of SARS-CoV-2 convalescent serum samples. This was a Phase 1, Randomized controlled trial, (observer blinded, dose escalation, on-going) with 195 patients who were Patients 18 to 55 years of age, deemed healthy, and adults 65 to 85 years of ages.

Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi PY, Türeci Ö, Tompkins KR, Lyke KE, Raabe V, Dormitzer PR, Jansen KU, Şahin U, Gruber WC. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med. 2020 Dec 17;383(25):2439-2450. doi: 10.1056/NEJMoa2027906. Epub 2020 Oct 14. PMID: 33053279; PMCID: PMC7583697.